Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBioPharma Dive ↗
The latest results give investors confidence in the drug's ability to be approved in another indication for wh…
The WeekPharmaVoice ↗
Strain selection timing and mRNA skepticism could limit the impact of Moderna's game-changing mRNA flu shot.…
The WeekFiercePharma ↗
This week on "The Top Line," Fierce's Fraiser Kansteiner sits down with Andy Deubler, chief business and admin…
The WeekFierceBiotech ↗
AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowin…
The WeekBriefing
Bristol Myers Squibb’s Zenbexus became the first approved CELMoD and the first new myeloma drug cleared direct…
The WeekPharmaceutical Technology ↗
Phanes Therapeutics has received fast track designation from the US FDA for spevatamig to treat patients with …
The WeekSTAT News ↗
The California trip shows how Kennedy likes to focus on key MAHA themes, while avoiding some divisive topics.…
The WeekFiercePharma ↗
With the European Union formally reversing its marketing authorization for the rare-disease med Tavneos last w…
The WeekFierceBiotech ↗
Capricor Therapeutics has bounced back from a bruising FDA advisory committee meeting by securing a green ligh…
The WeekBriefing
FDA set a September 16 public meeting on PDUFA reauthorization for FY 2028 through 2032. The notice starts the…
The WeekFiercePharma ↗
A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of …
The WeekFierceBiotech ↗
Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pha…
The WeekBriefing
FDA’s August 14 update added fresh detail to the agency’s running list of withdrawn cancer accelerated approva…
The WeekSTAT News ↗
Epic Systems is the subject of a broad inquiry into its business practices, people who were contacted by FTC i…
The WeekSTAT News ↗
Every parent experiences a unique mix of emotions when caring for a newborn baby. You're filled with an overwh…
The WeekBioPharma Dive ↗
The clearance of Zenbexus is the first for a group of protein-degrading "CELMoD" medicines that could help Bri…
The WeekPharmaVoice ↗
BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixe…
The WeekBioPharma Dive ↗
The FDA is "willing to review" an updated submission for Capricor's Duchenne cell therapy, its CEO said. Elsew…
The WeekPharmaVoice ↗
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transit…
The WeekBioPharma Dive ↗
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs - but experts say money …
The WeekFiercePharma ↗
With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next mon…
The WeekFierceBiotech ↗
Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going …
The WeekBriefing
ICER’s draft review found Baxfendy too expensive relative to its assessed benefit at current WAC-based pricing…
The WeekDrug Channels ↗
Today's guest post comes from Josh Marsh, Vice President and General Manager at Cardinal Health Sonexus™ Acces…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.